Chromatin mechanism of molecular motor gene regulation
Chromatin mechanism of molecular motor gene regulation
批准号:
8695542
负责人:
CHING-PIN CHANG
金额:
$37.13万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-06-01 至 2017-05-31
关键词:
ATP phosphohydrolaseAcetylationAnimal ModelCardiacCardiac MyocytesCardiomyopathiesChemicalsChromatinCo-ImmunoprecipitationsCpG dinucleotideDNADNA MethylationDNA MethyltransferaseDNA Modification MethylasesDNA methyltransferase inhibitionDevelopmentDrug TargetingEnvironmentFailureGene ExpressionGene Expression RegulationGene SilencingGenesGeneticHeartHeart ContractilitiesHeart HypertrophyHeart failureHistone DeacetylaseHistonesHumanHypertrophyKnock-outLeftLeft ventricular structureLysineMammalsMethodsMethylationMolecularMolecular BiologyMolecular MotorsMorbidity - disease rateMusMuscle ContractionMyocardiumMyopathyMyosin Heavy ChainsOperative Surgical ProceduresOutcomePatientsPerformancePharmaceutical PreparationsProcessProtein IsoformsRepressionResearchResistanceSeveritiesSocietiesStressVentricular Cardiac alpha-MyosinWorkbasechromatin immunoprecipitationchromatin remodelingdesignhistone methyltransferaseimprovedinhibitor/antagonistinsightmortalitypressurepreventprogramspromoterscaffoldsmall moleculetherapeutic targettool
中文摘要
描述(由申请人提供):病理性应激诱导心肌转录基因重编程,导致肌病和心力衰竭。然而,关于病理性应激如何触发染色质重组以控制肌病基因表达,人们知之甚少。本研究计划的重点是不同的染色质调节因子如何协同作用,以建立抑制染色质环境来控制α -肌球蛋白重链(¿-MHC)的表达,这是一种分子运动基因,其在应激心脏中的抑制有助于肌病和心力衰竭。四种不同的染色质调节因子-染色质重塑酶,组蛋白甲基转移酶,组蛋白去乙酰化酶和DNA甲基转移酶-将检查他们协同抑制¿-MHC。由于化学抑制剂可以抑制这些染色质因子,因此有可能开发出药物来提高衰竭心脏中的MHC,从而改善心脏功能。了解这些染色质因子(药物靶点)如何相互作用将有助于我们设计新药,并了解抑制不同类别染色质调节因子的潜在药物的协同作用/动力学。目的1:确定mhc抑制和心力衰竭所需的DNA甲基转移酶的特定亚型。我们将敲除小鼠心肌中的DNA甲基转移酶异构体,并检查对应激心脏中-MHC抑制和心力衰竭进展的影响。目的2:确定染色质重塑剂如何整合组蛋白和DNA甲基转移酶来沉默-MHC。我们将使用动物模型、手术方法和各种分子生物学方法(染色质免疫沉淀和定量PCR)来定义这些染色质因子之间的相互作用,这些染色质因子对组蛋白和DNA甲基化至关重要。目的3:确定组蛋白去乙酰化酶如何与组蛋白和DNA甲基转移酶协同抑制-MHC启动子。我们将使用动物模型、手术方法和各种分子生物学方法(染色质免疫沉淀、定量PCR和共免疫沉淀)来定义这些染色质因子之间的相互作用,这些因子对组蛋白甲基化和乙酰化以及¿-MHC启动子的DNA甲基化至关重要。
英文摘要
DESCRIPTION (provided by applicant): Pathological stress induces transcriptional gene reprogramming in the heart muscle, leading to myopathy and heart failure. However, little is known about how the pathological stress triggers the restructuring of chromatin to control myopathic gene expression. This research program focuses on how different chromatin-regulating factors act in concert to establish a repressive chromatin environment to control the expression of alpha-myosin heavy chain (¿-MHC), a molecular motor gene whose repression in the stressed hearts contributes to myopathy and heart failure. Four different chromatin regulators-chromatin remodeler, histone methyltransferase, histone deacetylase and DNA methyltransferase-will be examined for their collaborative repression of ¿-MHC. Because chemical inhibitors are available to inhibit these chromatin factors, it is possible to develop drus to boost ¿- MHC in the failing heart to improve cardiac function. Understanding how these chromatin factors (drug targets) interact will help us design new drugs and understand the synergy/dynamics of potential drugs that inhibit different classes of chromatin regulators. Aim 1: Defining specific isoforms of DNA methyltransferase required for ¿-MHC repression and heart failure. We will knock out DNA methyltransferase isoforms in the heart muscle of mice and examine the effects on ¿-MHC repression in the stressed heart and on the progression of heart failure. Aim 2: Determine how chromatin remodeler integrates histone and DNA methyltransferases to silence ¿-MHC. We will use animal models, surgical method, and various molecular biology methods (chromatin immunoprecipitation and quantitative PCR) to define the interactions between these chromatin factors crucial for the histone and DNA methylation of ¿-MHC. Aim 3: Defining how histone deacetylase coordinates with histone and DNA methyltransferases to repress ¿-MHC promoter. We will use animal models, surgical methods, and various molecular biology methods (chromatin immunoprecipitation, quantitative PCR, and co-immunoprecipitation) to define the interactions between these chromatin factors that are essential for histone methylation and acetylation, as well as DNA methylation of ¿-MHC promoter.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
LncRNA mechanism of heart failure
-
批准号:10053994
-
项目类别:
-
资助金额:$51.54万
-
财政年份:2020
-
负责人:CHING-PIN CHANG
-
依托单位:
LncRNA mechanism of heart failure
-
批准号:10228684
-
项目类别:
-
资助金额:$54.97万
-
财政年份:2020
-
负责人:CHING-PIN CHANG
-
依托单位:
LncRNA mechanism of heart failure
-
批准号:10021030
-
项目类别:
-
资助金额:$54.92万
-
财政年份:2020
-
负责人:CHING-PIN CHANG
-
依托单位:
LncRNA mechanism of heart failure
-
批准号:10441319
-
项目类别:
-
资助金额:$54.97万
-
财政年份:2020
-
负责人:CHING-PIN CHANG
-
依托单位:
LncRNA mechanism of heart failure
-
批准号:8826621
-
项目类别:
-
资助金额:$39.49万
-
财政年份:2014
-
负责人:CHING-PIN CHANG
-
依托单位:
LncRNA mechanism of heart failure
-
批准号:9037706
-
项目类别:
-
资助金额:$40.15万
-
财政年份:2014
-
负责人:CHING-PIN CHANG
-
依托单位:
LncRNA mechanism of heart failure
-
批准号:9246562
-
项目类别:
-
资助金额:$40.22万
-
财政年份:2014
-
负责人:CHING-PIN CHANG
-
依托单位:
LncRNA mechanism of heart failure
-
批准号:8612415
-
项目类别:
-
资助金额:$40.04万
-
财政年份:2014
-
负责人:CHING-PIN CHANG
-
依托单位:
Chromatin mechanism of molecular motor gene regulation
-
批准号:8851672
-
项目类别:
-
资助金额:$38.42万
-
财政年份:2013
-
负责人:CHING-PIN CHANG
-
依托单位:
Chromatin mechanism of molecular motor gene regulation
-
批准号:8666043
-
项目类别:
-
资助金额:$38.22万
-
财政年份:2013
-
负责人:CHING-PIN CHANG
-
依托单位:
Mechanisms of Neural Crest Cell Development
-
批准号:7837469
-
项目类别:
-
资助金额:$35.42万
-
财政年份:2009
-
负责人:CHING-PIN CHANG
-
依托单位:
Mechanisms of Neural Crest Cell Development
-
批准号:7416750
-
项目类别:
-
资助金额:$38.28万
-
财政年份:2006
-
负责人:CHING-PIN CHANG
-
依托单位:
Mechanisms of Neural Crest Cell Development
-
批准号:7625060
-
项目类别:
-
资助金额:$38.29万
-
财政年份:2006
-
负责人:CHING-PIN CHANG
-
依托单位:
Mechanisms of Neural Crest Cell Development
-
批准号:7132533
-
项目类别:
-
资助金额:$39.39万
-
财政年份:2006
-
负责人:CHING-PIN CHANG
-
依托单位:
Mechanisms of Neural Crest Cell Development
-
批准号:7260530
-
项目类别:
-
资助金额:$38.26万
-
财政年份:2006
-
负责人:CHING-PIN CHANG
-
依托单位:
Mechanisms of Nural Crest Cell Development
-
批准号:7848218
-
项目类别:
-
资助金额:$38.31万
-
财政年份:2006
-
负责人:CHING-PIN CHANG
-
依托单位:
海外基金